Stuart Therapeutics
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- $11M
Investors
- 3
About Stuart Therapeutics
Stuart Therapeutics, Inc.Founded in 2017 and headquartered in Stuart, US, Stuart Therapeutics, Inc. specializes in the advancement of ocular therapies.Stuart Therapeutics specializes in the development of innovative therapies targeting chronic eye diseases through its proprietary platform technology, PolyCol TM. The core product offerings focus on a synthetic protein designed to repair disease-damaged helical collagen within the extracellular matrix, which plays a crucial role in maintaining healthy tissue in the eye. This technology aims to address conditions such as Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration (Dry AMD) by specifically binding to and repairing compromised collagen structures. The intended end users of these therapies include patients suffering from chronic ocular conditions, healthcare providers, and ophthalmologists, primarily in the United States and Europe.Stuart Therapeutics generates revenue through strategic partnerships, collaborations, and licensing agreements with pharmaceutical companies and healthcare providers within the ophthalmology sector. These transactions typically involve the licensing of their PolyCol TM technology for further development and commercialization, aligning with established firms focused on eye care solutions. The company is engaged in B2B relationships where the end products are distributed through healthcare systems, specialty pharmacies, and surgical centers. Pricing structures for their offerings may vary based on the nature of agreements, potential milestones in product development, and the specific therapeutic applications addressed. The company is also exploring avenues for expanding into additional markets within the ophthalmology sector, with a focus on European regions by 2023, aiming to broaden their reach and impact in treating chronic eye diseases.
Who invested in Stuart Therapeutics
3 investors across 1 round
See all investors in Stuart Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 19, 2021
Amount
$11M
Investors
Questions about Stuart Therapeutics
Who invested in Stuart Therapeutics?
Stuart Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Stuart Therapeutics raised?
Stuart Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Stuart Therapeutics last raise money?
Stuart Therapeutics's most recent round on record is a Series A, in Mar 2021.
What does Stuart Therapeutics do?
Stuart Therapeutics is a biotechnology company.
Where is Stuart Therapeutics headquartered?
Stuart Therapeutics is headquartered in Stuart, US.
Which VCs invest in companies like Stuart Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Stuart Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Stuart Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.